Status:
COMPLETED
Effects of Optimized Antiplatelet Treatment After Percutaneous Coronary Intervention
Lead Sponsor:
Shenyang Northern Hospital
Conditions:
Ischemic Heart Disease
Acute Coronary Syndromes
Eligibility:
All Genders
35-75 years
Phase:
PHASE4
Brief Summary
Effects of dual antiplatelet therapy with aspirin and clopidogrel after percutaneous coronary intervention has been proven. However, patients with low response to those agents are reported be associat...
Eligibility Criteria
Inclusion
- non-ST-segment elevated acute coronary syndromes
- patients undergoing selective or emergent PCI
Exclusion
- administration of clopidogrel or ticlopidine within 2 weeks
- ST-segment elevated myocardial infarction
- contraindications of antiplatelet therapy
- history of intracranial bleeding
- known bleeding disorders
- severe liver or kidney disease
Key Trial Info
Start Date :
June 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2007
Estimated Enrollment :
305 Patients enrolled
Trial Details
Trial ID
NCT00404781
Start Date
June 1 2006
End Date
June 1 2007
Last Update
October 14 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Northern Hospital
Shenyang, Liaoning, China, 110016